- ￥8343.92
- Abd Serotec
- 英国
- HCA237
- 2025年10月06日
- E
- HuCAL
- Human
企业认证
相关产品推荐更多 >
![Prothrombin antibody [9013]](https://img1.dxycdn.com/2023/0711/451/6106825198874858761-14.jpg!wh200)
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 形态：
液体
- 保存条件：
4度
- 克隆性：
Monoclonal Antibody
- 标记物：
Purified
- 适应物种：
Human
- 宿主：
HuCAL
- 应用范围：
E
- 浓度：
请参考说明书
- 靶点：
OMALIZUMAB
- 抗体英文名：
HUMAN ANTI OMALIZUMAB (DRUG/TARGET COMPLEX)
- 抗体名：
HUMAN ANTI OMALIZUMAB (DRUG/TARGET COMPLEX)
- 规格：
0.1 mg
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验A screen to identify drug resistant variants to target-directed anti-cancer agents
The discovery of oncogenes and signal transduction pathways important for mitogenesis has triggered the development of target-specific small molecule anti-cancer compounds. As exemplified by imatinib (Gleevec), a specific inhibitor of the Chronic
Biocomputational Strategies for Microbial Drug Target Identification
aeruginosa as an example. The resultant analyses are in good agreement with the results of systematic gene deletion experiments. This strategy enables rapid potential drug target identification, thereby greatly facilitating the search for new antibiotics
Antibodies are emerging as a new drug class with many of these approved and marketed. Antibodies may be non-human, chimeric, humanized or fully human. All these have the potential to elicit an immune response in the host which may impact
技术资料暂无技术资料 索取技术资料
